Literature DB >> 32363092

Immunohistochemical Evaluation and Clinicopathological Correlation of Mer and Axl Tyrosine Kinase TAM Receptors in Cutaneous Melanoma.

Andrea Pontara1, Giovanni Paolino2,3, Vanesa Gregorc4, Santo Raffaele Mercuri2, Alessandra Bulotta4, Pietro Bearzi2, Claudio Doglioni5, Nathalie Rizzo5.   

Abstract

BACKGROUND: Malignant melanoma (MM) is potentially the most dangerous form of skin tumor. In the last few years, the so-called TAM receptors, a unique family of tyrosine kinase (TK) receptors, have become increasingly important.
OBJECTIVES: To evaluate Mer and Axl TAM receptor expression to find clinicopathological features that could explain the biological behavior of MM. PATIENTS AND METHODS: Clinicopathological data were obtained from an MM electronic database at our Institute. We reviewed 24 cutaneous MM specimens. TAM receptor expression was assayed using immunohistochemistry. Combinative semiquantitative scoring was used for the evaluation of TAM receptor expression (MerTK and AxlTK). Appropriate statistical methods were used to evaluate a possible correlation between TAM receptor expression and the clinicopathological variables of the MM samples (univariate analysis and multivariate analysis).
RESULTS: MerTK and AxlTK were expressed differently in the MM samples, with a major expression of the first receptor. The cells of the tumor microenvironment contributed to the majority of the total score. A significant association was found between AxlScore and the site of the tumor and between AxlScore and the variable ulceration; another correlation was found between MerScore and the following characteristics: pathological stage of the tumor (pT), sex, ulceration, and tumor-infiltrating lymphocytes.
CONCLUSIONS: All correlations between the expression of MerTK and AxlTK with the clinical and histological variables of MM should be validated in a large group of people in order to increase the validity and the impact of our observations, with subsequently therapeutic implications in the era of the "targeted therapy." ©2020 Pontara et al.

Entities:  

Keywords:  Axl; Mer; TAM; malignant melanoma; receptors; therapy; tyrosine kinase

Year:  2020        PMID: 32363092      PMCID: PMC7190557          DOI: 10.5826/dpc.1002a29

Source DB:  PubMed          Journal:  Dermatol Pract Concept        ISSN: 2160-9381


  18 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  Vitamin D receptor immunohistochemistry variability in sun-exposed and non-sun-exposed melanomas.

Authors:  Giovanni Paolino; Chiara Panetta; Carlo Cota; Dario Didona; Elisa Moliterni; Cinzia Di Mattia; Gaetano De Vita; Ugo Bottoni; Pietro Donati; Stefano Calvieri
Journal:  Melanoma Res       Date:  2017-02       Impact factor: 3.599

4.  Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

Authors:  J B A G Haanen; A Baars; R Gomez; P Weder; M Smits; T D de Gruijl; B M E von Blomberg; E Bloemena; R J Scheper; S M van Ham; H M Pinedo; A J M van den Eertwegh
Journal:  Cancer Immunol Immunother       Date:  2005-07-21       Impact factor: 6.968

5.  MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

Authors:  Jennifer Schlegel; Maria J Sambade; Susan Sather; Stergios J Moschos; Aik-Choon Tan; Amanda Winges; Deborah DeRyckere; Craig C Carson; Dimitri G Trembath; John J Tentler; S Gail Eckhardt; Pei-Fen Kuan; Ronald L Hamilton; Lyn M Duncan; C Ryan Miller; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Jing Liu; Weihe Zhang; Chao Yang; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Janiel M Shields; Douglas K Graham
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

6.  MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.

Authors:  Kathryn A Tworkoski; James T Platt; Antonella Bacchiocchi; Marcus Bosenberg; Titus J Boggon; David F Stern
Journal:  Pigment Cell Melanoma Res       Date:  2013-05-21       Impact factor: 4.693

7.  Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.

Authors:  Ki Rang Moon; Yoo Duk Choi; Jung Min Kim; Suna Jin; Min-Ho Shin; Hyun-Jeong Shim; Jee-Bum Lee; Sook Jung Yun
Journal:  J Invest Dermatol       Date:  2017-11-27       Impact factor: 8.551

8.  A genomic screen identifies TYRO3 as a MITF regulator in melanoma.

Authors:  Shoutian Zhu; Heiko Wurdak; Yan Wang; Anna Galkin; Haiyan Tao; Jie Li; Costas A Lyssiotis; Feng Yan; Buu P Tu; Loren Miraglia; John Walker; Fanxiang Sun; Anthony Orth; Peter G Schultz; Xu Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

9.  NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Authors:  Katarina Omholt; Anton Platz; Lena Kanter; Ulrik Ringborg; Johan Hansson
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

10.  The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.

Authors:  Satu Salmi; Hanna Siiskonen; Reijo Sironen; Kristiina Tyynelä-Korhonen; Benjamin Hirschovits-Gerz; Mari Valkonen; Päivi Auvinen; Sanna Pasonen-Seppänen
Journal:  Melanoma Res       Date:  2019-06       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.